Skip to content

Trial Summary

This trial will study Ladiratuzumab Vedotin (LV) to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur.

Acronym:

SEAGEN SGNLVA

ACTRN/NCT /ethics:

NCT04032704

Scientific title:

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Sponsor / Cooperative group:

Seattle Genetics, Inc.

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2019-10-09
Anticipated End Date2021-04-30

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorDr Chris Karapetis
Recruitment StatusNot Yet Recruiting